Waypoint Bio raises $20M in Series A funding to run three CAR-T trials in China.
PRIVATEMay 27, 2026
Amount Raised
$20 Million
Round Type
Series A
New YorkBiotechnologyHealth CareTherapeutics
Description
New York City-based startup Waypoint Bio has raised $20 million in Series A financing. The funding will be used to test multiple cell therapies in China. This round is aimed at advancing the company's clinical trials.
Who to call at Waypoint Bio, and when
A new round usually means Waypoint Bio is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Waypoint Bio raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Waypoint Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Waypoint Bio. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Waypoint Bio
Location
New York, New York, United States
About
Waypoint Bio is a biotechnology company pioneering novel cell therapies for solid tumors using in vivo spatial pooled screening technology. The company's platform uniquely combines spatial biology with pooled screening for the purpose of drug discovery, enabling the simultaneous measurement of cell therapy candidates' navigation in the solid tumor microenvironment. Waypoint will use its seed financing toward designing CAR T-cell therapies with superior efficacy against the tumor microenvironment, and later, Treg therapies for autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Waypoint Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth CareTherapeutics